ADC Therapeutics SA
Close on Oct 19, 2026
- Market cap
- $223.22M
- P/E (TTM)
- –
- Dividend yield
- –
About ADC Therapeutics
Pharmaceutical Preparations, SIC 2834
ADC Therapeutics is a commercial-stage biotechnology company focused on developing antibody drug conjugates to treat cancer. Its primary commercial product is ZYNLONTA, a CD19-directed therapy approved for adult patients with relapsed or refractory diffuse large B-cell lymphoma who have received two or more lines of systemic treatment. The company also investigates expanded clinical applications for ZYNLONTA across earlier therapy lines and combinations, while advancing pipeline candidates such as ADCT-241 for prostate cancer. In the United States, it commercializes its medicine directly through pharmaceutical wholesale distributors that supply hospitals and oncology healthcare providers.
The enterprise maintains an international presence through strategic agreements and operational hubs. Its commercial partnerships and licensing arrangements cover markets across Europe, Japan, China, and Canada, while third-party contract manufacturing organizations produce its therapeutic compounds. ADC Therapeutics is headquartered in Lausanne, Switzerland, and runs operational facilities in New Jersey.
Summary of the business section of ADC Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ADC Therapeutics SA
- Headquarters
- Epalinges, V8
- Address
- Biopole, Route De La Corniche 3b 1066
- Phone
- 41 21 653 02 00
- Employees
- 188, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- V8
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers SA, Lausanne, Switzerland
Stock & identifiers
- Ticker
- ADCT
- Exchange
- NYSE
- IPO date
- May 18, 2020
- Shares outstanding
- 128M, Aug 3, 2026
- Public float
- $136.40M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1771910
- CUSIP
- H0036K147
- ISIN
- USH0036K1476
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ameet Mallik | Chief Executive Officer, Director | 2,790,870 |
| Mohamed Zaki | Chief Medical Officer | 896,317 |
| Peter J. Graham | Chief Legal Officer | 841,640 |
| Jose Carmona | Chief Financial Officer | 938,076 |
| Lisa Michelle Kallebo | Chief Accounting Officer | 128,224 |
| Viviane Monges | Director | 186,447 |
| Victor Sandor | Director | 140,686 |
| Robert Azelby | Director | 112,805 |
| Timothy Coughlin | Director | 72,400 |
| Jean-Pierre Bizzari | Director | 139,302 |
| Ron Squarer | Director | 123,431 |
| Peter Hug | Director | 263,344 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $2.45M | $6.05M | $1.38M | $92 | – |
| FY2024 | $1.84M | $4.13M | $971.55K | $52 | – |
| FY2023 | $3.78M | $2.68M | $2.83M | $43 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 188 full-time employees and five part-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 18, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| May 11, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
| Sep 30, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |